A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: A single center experience from China

Journal of Hematology and Oncology

Volumn 2, Issue , 2009, Pages

  Wang, Jianmin ^a   Lü, Shuqing ^a   Yang, Jianmin ^a   Song, Xianmin ^a   Chen, Li ^a   Huang, Chongmei ^a   Hou, Jun ^a   Zhang, Weiping ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE; IDARUBICIN; MITOXANTRONE; ANTINEOPLASTIC AGENT; HARRINGTONINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AGED HOSPITAL PATIENT; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CHINA; DRUG ADMINISTRATION; EVALUATION; MIDDLE AGED; MORTALITY; REMISSION; SURVIVAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 69249219029     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-2-32     Document Type: Article

References (21)

1. Cytosine arabinoside with daunorybicin or adriamycin therapy with acute myelocytic leukemia: a CALGB study. J Yates O Glidewell P Wiernik MR Cooper D Steinberg H Dosik R Levy C Hoagland P Henry A Gottlieb C Cornell J Berenberg JL Hutchison P Raich N Nissen RR Ellison R Frelick GW James G Falkson RT Silver F Haurani M Green E Henderson L Leone JF Holland, Blood 1982 60 454 463 6953986
2. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. E Berman G Heller J Santorsa S McKenzie T Gee S Kempin S Gulati M Andreeff J Kolitz J Gabrilove L Reich K Mayer D Keefe K Trainor A Schluger D Penenberg V Raymond R O'Reilly S Jhanwar C Young B Clarkson, Blood 1991 77 1666 1674 2015395
3. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. PH Wiernik PL Banks DC Case Jr ZA Arlin PO Periman MB Todd PS Ritch RE Enck AB Weitberg, Blood 1992 79 313 319 1730080
4. The benefit of induction chemotherapy in patients age > or = 75 years. N Vey D Coso VJ Bardou AM Stoppa AC Braud R Bouabdallah D Sainty MJ Mozziconacci M Lafage G Damaj D Blaise JA Gastaut D Maraninchi, Cancer 2004 101 325 331 10.1002/cncr.20353 15241830 (Pubitemid 38890836)
5. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001. V Alymara E Tzouvara G Vartholomatos A Chaidos S Tsiara KL Bourantas, J Exp Clin Cancer Res 2004 23 447 454 15595635
6. Homoharringtonine: an effective new natural product in cancer chemotherapy. DC Zhou R Zittoun JP Marie, Bull Cancer 1995 82 987 995 8745664
7. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. J Jin DZ Jiang WY Mai HT Meng WB Qian HY Tong J Huang LP Mao Y Tong L Wang ZM Chen WL Xu, Leukemia 2006 20 1361 1367 10.1038/sj.leu.2404287 16791270 (Pubitemid 44084048)
8. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. R Tang AM Faussat P Majdak JY Perrot D Chaoui O Legrand JP Marie, Mol Cancer Ther 2006 5 723 731 10.1158/1535-7163.MCT-05-0164 16546987
9. omoharringtonine: a new treatment option for myeloid leukemia. CY Luo JY Tang YP Wang, Hematology 2004 9 259 270 10.1080/10245330410001714194 15621733 (Pubitemid 39359346)
10. Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP). L Yinjun J Jie X Weilai T Xiangming, Am J Hematol 2004 76 199 204 10.1002/ajh.20100 15224352 (Pubitemid 38828836)
11. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. EJ Feldman KP Seiter T Ahmed P Baskind ZA Arlin, Leukemia 1996 10 40 42 8558935
12. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. A Pigneux V Perreau E Jourdan N Vey N Dastugue F Huguet JJ Sotto LR Salmi N Ifrah J Reiffers, Haematologica 2007 92 1327 1334 10.3324/haematol.11068 18024370 (Pubitemid 350153468)
13. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. A Pigneux V Perreau E Jourdan N Vey N Dastugue F Huguet JJ Sotto LR Salmi N Ifrah J Reiffers, Br J Haematol 2003 123 810 818 10.1046/j.1365-2141.2003.04702.x 14632771 (Pubitemid 37533292)
14. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. FJ Giles S Faderl DA Thomas JE Cortes G Garcia-Manero D Douer AM Levine CA Koller SS Jeha SM O'Brien EH Estey HM Kantarjian, J Clin Oncol 2003 21 1050 1056 10.1200/JCO.2003.04.023 12637470 (Pubitemid 46594134)
15. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001. V Alymara E Tzouvara G Vartholomatos A Chaidos S Tsiara KL Bourantas, J Exp Clin Cancer Res 2004 23 447 454 15595635
16. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. FJ Giles HM Kantarjian JE Cortes S Faderl S Verstovsek D Thomas G Garcia-Manero W Wierda A Ferrajoli S Kornblau GN Mattiuzzi AM Tsimberidou M Albitar SM O'Brien E Estey, Leuk Res 2005 29 649 652 10.1016/j.leukres.2004.11.013 15863204 (Pubitemid 40603564)
17. Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial. RF Schlenk S Fröhling F Hartmann, Leukemia 2006 20 748 750 10.1038/sj.leu.2404122 16437135
18. A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients. A Olivieri D Capelli E Troiani A Poloni M Montanari M Offidani G Discepoli P Leoni, Exp Hematol 2007 5 1074 1082 10.1016/j.exphem.2007.03.013 (Pubitemid 46921303)
19. pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia. JH Baek SK Sohn DH Kim JG Kim DH Yang YK Kim JJ Lee HJ Kim, Acta Haematol 2007 117 109 114 10.1159/000097386 17135724 (Pubitemid 46272251)
20. Eastern Cooperative Oncology. A phase 3 study of three induction protocols and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. JM Rowe D Neuberg W Friedenberg JM Bennett E Paietta AZ Makary JL Liesveld CN Abboud G Dewald FA Hayes MS Tallman PH Wiernik, Blood 2004 103 479 485 10.1182/blood-2003-05-1686 14512295 (Pubitemid 38140076)
21. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. JE Anderson KJ Kopecky CL Willman D Head MR O'Donnell FW Luthardt TH Norwood IM Chen SP Balcerzak DB Johnson FR Appelbaum, Blood 2002 100 3869 3876 10.1182/blood-2001- 12-0354 12393614 (Pubitemid 35396851)